Safety of Extended Pirtobrutinib Exposure in Relapsed and/or Refractory B-Cell Malignancies. Roeker LE, Coombs CC, Shah NN, Jurczak W, et al. Acta Haematol 2025;148:180-197.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Roeker LE, Coombs CC, Shah NN, Jurczak W, et al. Safety of Extended Pirtobrutinib Exposure in Relapsed and/or Refractory B-Cell Malignancies. Acta Haematol 2025;148:180-197.
PMID: 38824917